Breaking Down Novavax’s Coronavirus Vaccine Data: 2 Analyst Takes

Novavax, Inc. (NASDAQ: NVAX) shares were roaring higher Friday after the company reported topline results from the late-stage trial of its coronavirus vaccine candidate in the U.K.

The Novavax Analyst: H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating and $207 price target for Novavax shares.

Novavax Regulatory News As A Positive Catalyst: Novavax’s NVX-CoV2373 is now firmly in line to become the fifth COVID-19 vaccine authorized, and upon a positive outcome from the ongoing PREVENT-19 Phase 3 trial in the U.S. and Mexico, potentially the fourth authorized in the U.S., H.C. Wainwright analyst Bernardino said in a note.

The protein-based vaccine candidate showed 96% efficacy against the SARS-CoV-2 original strain and 86% efficacy against the emergenct U.K. strain, the analyst said.

Data from the Phase 2b study conducted in South Africa against an emergent strain showed a lower efficacy, he said.

Bernardino shrugged off the lower efficacy data from the South African trial.

“However, we view the South Africa studies as positive, as they point to positive implications regarding the potential for Novavax’s vaccines to confer cross-protection, as has been observed with NanoFlu, the company’s investigational quadrivalent seasonal influenza vaccine.”

With data from Phase 1, 2 and 3 trials that involved over 20,000 participants, Novavax is in a strong position to gain authorization for use of NVX-CoV2373 in the U.K., Bernardino said.

The company has initiated a rolling submission for the vaccine candidate in the U.K., the analyst said.

Regulatory updates could be positive catalysts in the first quarter of 2021, he said.

Bernardino expects a potential interim analysis of PREVENT-19 Phase 3 trial being conducted in the U.S. and Mexico in early February and a potential final analysis as early as the end of February 2021.

“NVX-CoV2373, which Novavax expects to ship in ready-to-use liquid formulation, is stable under refrigeration conditions (2°C to 8°C), permitting use of existing vaccine supply chain channels,” the analyst said.

Story continues

The company has manufacturing and supply deals in eight geographies around the world, and annual capacity of over 2 billion doses that the company expects to have in place by mid-2021, he said.

H.C. Wainwright said the scope and robustness of Novavax’s strategy to be the leader in COVID-19 vaccines remains underappreciated.

Related Link: The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO

Less Inspiring South African Data A Setback: The vaccine’s efficacy against the new variant in South Africa — B1.351 — may have been in the range of 55%-65%, SVB Leerink analyst Geoffrey Porges said.

“Reducing efficacy against the variant virus is a major blow to any plans to the vaccines to achieve herd immunity in the immediate future against the virus,” the analyst said.

Yet the vaccine candidate should not be considered as “not clinically useful” against the variant, given a tolerable safety profile and evidence of effective reduction in severe disease, he said.

For Novavax, the data amounts to a tremendous success, despite the alarming implications of B1.351 and similar variants, the analyst said. The company has validated their platform, and confirmed the promise shown by their very high titer of antibodies and robust T cell responses in animals and earlier human trials, Porges said.

“They have a clear path to approval and commercial sale of their first product, and given their favorable product characteristics, should see widespread purchase and adoption.”

Ultimately, Novavax is well-positioned to develop a combined multi-valent influenza/COVID-19 vaccine, and this may be its most compelling commercial opportunity longer term, according to SVB Leerink.

The firm also sees a positive read-across for other protein subunit vaccine developers such as Sanofi SA (NASDAQ: SNY)/ GlaxoSmithKline plc (NYSE: GSK), despite the need to use new antigen for their programs.

NVAX Price Action: Novavax shares were rallying by 66.2% to $222.73 at last check.

Related Link: The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More

Latest Ratings for NVAX

View More Analyst Ratings for NVAX
View the Latest Analyst Ratings

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.